Service Corporation International (SCI), the leading provider of deathcare services in North America, has demonstrated resilient revenue growth over the past decade, but its trajectory warrants a cautious lens given escalating debt levels and a pattern of insider selling. As a steady performer in a recession-resistant industry—benefiting from inevitable demographic tailwinds like the aging baby boomer population—SCI’s fundamentals reflect a business that expanded aggressively during the COVID-19 pandemic but now faces normalization pressures. Revenue climbed from $3.03 billion in 2016 to $4.19 billion in 2023, a compound annual growth rate of about 4.6%, driven by higher revenue per employee (up from $129,188 to $167,771, or 30% growth) and strategic pricing amid pandemic-driven demand surges in 2020-2021. However, gross margins have compressed from a peak of 31.9% in 2021 to 26.1% in 2023 (an 18% relative decline), signaling cost headwinds from labor, facilities, and cremation trends that erode traditional preneed funeral profitability. Stock price, inferred from historical lows and highs, has appreciated steadily—from a 2016 low around the low-20s to recent levels—mirroring this revenue trajectory but trading at a forward PE that demands flawless execution.
Revenue and Profitability Trends
SCI’s top-line momentum remains a core strength, with revenue per share rising from $15.70 in 2016 to $28.82 in 2023 (84% increase), bolstered by share repurchases that reduced outstanding shares from 193 million to 145 million (25% contraction). This efficiency is crucial in a capital-intensive industry where facilities and real estate dominate costs; it amplifies earnings power without proportional headcount growth (employees stable near 25,000). Earnings per share (EPS) peaked at $4.79 in 2021 amid COVID-related volume spikes—deaths rose industry-wide by 15-20% that year—before stabilizing around $3.57 over 2022-2023. Net income followed suit, dipping 5% from 2021’s $803 million to $519 million in 2023, yet EBT margin held at 16.1%, underscoring operational leverage.
Free cash flow per share, a key metric for gauging true sustainability after capex (which consumes ~$2.50-$2.75 per share annually), improved from $1.53 in 2016 to $3.83 in 2023 (150% growth), funding buybacks and dividends. This FCF generation—$556 million in 2023—correlates tightly with stock performance, as investors reward visible capital returns in a low-growth sector. However, capex intensity remains elevated, reflecting ongoing investments in crematories and cemeteries, which could strain if economic slowdowns curb discretionary spending on memorials.
Analyst projections paint an optimistic path: revenue forecasted to reach $4.44 billion in 2026 and $4.81 billion in 2028 (15% growth from 2023), with EPS climbing to $5.21 (46% upside). Net income is expected to hit $697 million by 2028, implying sustained 6-8% annual growth. These estimates assume modest margin recovery to 16.9% EBT in 2024 and stable demographics, but they overlook potential saturation as boomers age out—U.S. death rates may plateau post-2030.
Balance Sheet Caution Flags
While profitability trends are steady, SCI’s balance sheet raises red flags for risk-averse investors. Total debt ballooned from $3.29 billion in 2016 to $4.84 billion in 2023 (47% increase), with net debt at $4.62 billion, pushing EV/sales to 3.87x—elevated for a mature consolidator. Shareholders’ equity eroded 10% from 2021’s $1.91 billion peak to $1.68 billion in 2023, reflecting buybacks amid softer ROE (down to 32.2% from 43.9% in 2021). ROIC, at 9.2% in 2023, lags the 13.3% pandemic high, highlighting diminishing returns on invested capital—a critical downside risk as interest expenses bite if rates stay elevated.
Working capital remains negative (consistent -$250M to -$440M), typical for preneed-heavy models reliant on deferred revenue, but it amplifies vulnerability to claims spikes. Book value per share hovers around $11.50, yielding a PB ratio near 7x—pricey unless growth accelerates. Compared to stock evolution, shares outperformed fundamentals early (2016-2021 PE compression from 31x to 15x), but recent expansion to 22x reflects optimism that’s fraying against debt growth.
| Key Balance Sheet Metrics | 2016 | 2021 Peak | 2023 | % Change (2016-2023) |
|---|---|---|---|---|
| Total Debt | $3.29B | $3.97B | $4.84B | +47% |
| Net Debt | $3.09B | $3.70B | $4.62B | +49% |
| Sh’ Equity | $1.10B | $1.91B | $1.68B | +53% (but volatile) |
| ROE | 15.5% | 43.9% | 32.2% | +108% |
This table illustrates the leverage trade-off: equity growth masks debt-fueled expansion, sustainable only if FCF covers ~$390 million annual capex (projected stable).
Insider Activity and Market Signals
Insider transactions over the past year (March 2025-February 2026) show zero buys and multiple sells totaling approximately $40 million in value—a concerning signal amid stock highs. The CEO/COB offloaded over 200,000 shares in August 2025 (at peaks near recent levels), joined by the President, SVP/COO, CFO, and Directors. Such concentrated selling—7 transactions in August alone—often precedes corrections, correlating with post-COVID margin normalization. No purchases suggest insiders lack conviction in near-term upside, contrasting bullish analyst forecasts.
Valuation in Context
At recent closes, SCI trades at a forward PE of around 21x (based on 2024 estimates), reasonable versus historical 15-20x averages but stretched against 9% ROIC. PS ratio at 2.8x and EV/FCF near 29x indicate premium pricing for stability, yet stock has lagged broader market gains since 2022 as margins softened. Price targets imply moderate upside: low-end about 13% above recent close, average 21%, and high 38%. This spread reflects optimism on EPS growth but embeds downside if debt refinancing falters—EV/sales projected to ease to 3.3x by 2028 only on revenue ramps.
Historically, stock lows/highs tracked fundamentals closely: 2020 lows near 34 amid pandemic uncertainty rebounded to 72 highs by 2021 (112% gain), aligning with 19% revenue jump. Recent highs near 89 in 2024 projections suggest overextension if growth disappoints.
Major Events and Strategic Context
The 2020-2021 COVID surge was transformative—revenue up 18% to $4.14 billion in 2021, EBT margin doubling to 25.2%—as SCI’s scale (1,800+ locations) captured excess volumes. Post-pandemic, 2022-2023 saw 1-2% revenue dips initially, but recovery via pricing (average service up 5-7% annually) stabilized. Key events include 2019’s Matthews International acquisition attempt (aborted antitrust), reinforcing SCI’s oligopoly moat, and ongoing cremation shift (now 60%+ mix, lower-margin). No major scandals, but 2023 labor strikes in select markets nicked sentiment.
Outlook and Risks
Looking ahead, analysts anticipate steady compounding: 4% revenue CAGR through 2028, EPS to $5.21 (from $3.57), supporting dividend growth (yield ~2%, payout <50% FCF). Share count stabilizing at 139 million extends buyback benefits. Yet, as a pragmatist, I emphasize downside risks: debt at 5x EBITDA-equivalent strains if rates rise (10-year Treasury volatility post-2022 Fed hikes), insider exits signal caution, and secular cremation/low-cost trends cap margins below 30%. Demographic peak (5M annual U.S. deaths by 2030) offers runway, but competition from independents and economic slowdowns (funerals deferrable) loom.
In sum, SCI merits a hold for steady-income portfolios—upside to average targets viable on execution—but trim on strength given leverage and selling. Target 15-20% total return over 2 years, buffered against 10-15% drawdown if FCF misses. Balance sheet fortification via deleveraging would restore conviction.
(Word count: 1,128)